Project Grant R01HL184520
Award Date 8/10/26
Completion Date 4/30/30
Dollars Obligated $702K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Utah $705,239 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on PET imaging as a tool to define mechanisms and stratify risk in arrhythmogenic cardiomyopathy. The recipient will integrate molecular imaging, immune profiling, and cardiac physiology in mechanistically relevant mouse models to test the hypothesis that positron emission tomography using...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Utah a $524,179 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) on September 5, 2025, to support research integrating multi-omics data to understand the heterogeneity of preeclampsia (PE) and long-term postpartum hypertension. The project will conduct a comprehensive analysis of whole genome sequencing (WGS) data from the NUMOM2B-HHS (Nulliparous Pregnancy Outcomes...
- The National Heart Lung and Blood Institute awarded the University of Utah $367,200 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolite transport modulation in myocardial ischemic-reperfusion injury. The research focuses on inhibition of monocarboxylate transporter 4 (MCT4), which regulates lactate excretion from cardiomyocytes, as a potential cardioprotective intervention following heart attack. The project comprises four specific...
- The National Heart, Lung, and Blood Institute awarded $108,656 to the University of Wisconsin–Madison on March 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize the molecular mechanisms of phospholamban R14DEL cardiomyopathy. The recipient will use high-resolution mass spectrometry–based proteomics, human clinical samples, and patient-specific human induced pluripotent stem cell–derived cardiomyocytes to investigate how cardiac proteoform alterations drive...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.272968 million on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-dependent regulation of cardiac cyclic AMP, excitation-contraction coupling, and arrhythmia by phosphodiesterases. The research addresses autonomic dysregulation and aberrant intracellular signaling in both heart failure with reduced ejection fraction and heart failure with...
- The National Heart, Lung, and Blood Institute awarded the University of California Irvine $235,500 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiac complications of dystrophin deficiency in female carriers of Duchenne muscular dystrophy. The research will examine how mosaic expression of dystrophin affects cardiomyocytes differentiated from human induced pluripotent stem cells of female carriers. The work will compare functional...
- The National Heart Lung and Blood Institute awarded the University of Utah $470,606 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the molecular mechanisms of smoking-induced endothelial dysfunction associated with the ALDH2*2 genetic variant. The research employs a multidisciplinary approach integrating stem cell biology, molecular biology, toxicology, vascular physiology, and endothelial mechanobiology to understand how tobacco consumption...
- The National Heart, Lung, and Blood Institute awarded the University of Utah $635,681 on June 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the pyruvate-lactate metabolic axis in heart failure and cardiac recovery. The research will quantify pyruvate-lactate metabolism in human heart failure and myocardial recovery; determine the essentiality of the pyruvate-lactate metabolic axis for heart failure and recovery; and define cell-autonomous mechanisms...
- The National Heart, Lung, and Blood Institute awarded the University of Utah $248,999 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for basic research into WNK1-dependent macropinocytosis and emergency myelopoiesis. The project investigates how the chloride-sensing kinase WNK1 regulates myeloid progenitor cell fate, particularly the shift from monocyte/macrophage lineage commitment toward emergency granulopoiesis during systemic infection. Research...
- The National Institutes of Health National Heart Lung and Blood Institute awarded $150,104 to The Regents Of The University Of Colorado (University of Colorado-Denver) on January 26, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for a Project Grant (F32HL179804) to investigate lysine myristoylation as a regulatory mechanism for protein kinase A (PKA) in cardiac tissue. The award funds research examining how histone deacetylase 11 (HDAC11) inhibition increases PKA...